LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells $999,197.85 in Stock

Key Points

• Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock at an average price of $92.39, resulting in a total transaction of nearly $999,198.
• LeMaitre Vascular reported a quarterly EPS of $0.60, exceeding the consensus estimate of $0.57, alongside a year-over-year revenue increase of 15%.
• The company has announced a quarterly dividend of $0.20 per share, payable on September 4th, with a current yield of 0.8%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director David B. Roberts sold 10,815 shares of the company's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the sale, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

LeMaitre Vascular Trading Up 0.3%

LMAT traded up $0.30 on Monday, reaching $96.21. 17,516 shares of the company traded hands, compared to its average volume of 188,956. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $84.56 and a two-hundred day simple moving average of $86.34. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58. The company has a market cap of $2.18 billion, a P/E ratio of 46.70, a price-to-earnings-growth ratio of 2.47 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same quarter in the previous year, the firm earned $0.52 EPS. The company's quarterly revenue was up 15.0% compared to the same quarter last year. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is 38.83%.

Wall Street Analyst Weigh In

LMAT has been the subject of several research reports. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald increased their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $98.00.

Institutional Trading of LeMaitre Vascular

Large investors have recently made changes to their positions in the business. Parkside Financial Bank & Trust lifted its stake in shares of LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 287 shares during the period. Opal Wealth Advisors LLC acquired a new stake in LeMaitre Vascular during the first quarter valued at $26,000. NBC Securities Inc. acquired a new stake in LeMaitre Vascular during the first quarter valued at $36,000. Geneos Wealth Management Inc. raised its position in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth $47,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.